Johnson Victoria A, Brun-Vezinet Francoise, Clotet Bonaventura, Conway Brian, Kuritzkes Daniel R, Pillay Deenan, Schapiro Jonathan M, Telenti Amalio, Richman Douglas D
Veterans Affairs Medical Center, Birmingham, AL, USA.
Top HIV Med. 2005 Oct-Nov;13(4):125-31.
The International AIDS Society-USA (IAS-USA) Drug Resistance Mutations Group is marking 5 years as an independent volunteer panel of experts focused on identifying key HIV-1 drug resistance mutations. The goal of the effort is to quickly deliver accurate and unbiased information on these mutations to HIV clinical practitioners. The October/November 2005 version of the IAS-USA Drug Resistance Mutations Figures replaces the version published in this journal in March/April 2005. The IAS-USA Drug Resistance Mutations Figures are designed for use in identifying mutations associated with viral resistance to antiretroviral drugs and in making therapeutic decisions. Care should be taken when using this list of mutations for surveillance or epidemiologic studies of transmission of drug-resistant virus. A number of amino acid substitutions, particularly minor mutations, represent polymorphisms that in isolation may not reflect prior drug selective pressure or reduced drug susceptibility.
美国国际艾滋病协会(IAS - USA)耐药性突变小组作为一个专注于识别关键HIV - 1耐药性突变的独立专家志愿者小组已满5周年。这项工作的目标是迅速向HIV临床从业者提供有关这些突变的准确且无偏见的信息。2005年10月/11月版的IAS - USA耐药性突变数据取代了2005年3月/4月在本期刊发表的版本。IAS - USA耐药性突变数据旨在用于识别与病毒对抗逆转录病毒药物耐药相关的突变以及做出治疗决策。在将此突变列表用于耐药病毒传播的监测或流行病学研究时应谨慎。一些氨基酸替代,尤其是微小突变,代表的多态性单独来看可能并不反映先前的药物选择压力或药物敏感性降低。